Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

Core Insights - Tevogen Bio has developed a significant asset portfolio since its founding in 2020 while maintaining expenditures under $40 million, which is a fraction of the industry norm [1][3] - The company focuses on building a disciplined and sustainable business model in the biotech sector, particularly in immunotherapy for infectious diseases and cancers [2][4] - Tevogen's leadership emphasizes the importance of preserving shareholder value and being cautious about equity dilution when considering financing options [3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company that develops off-the-shelf, genetically unmodified T cell therapies targeting infectious diseases, cancers, and neurological disorders [4][5] - The company has reported positive safety data from its proof-of-concept clinical trials and owns key intellectual property assets, including three granted patents and numerous pending patents [4] - Tevogen's leadership believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating innovative business models to sustain medical innovation [5]